30
Participants
Start Date
May 31, 2006
Primary Completion Date
October 31, 2010
Study Completion Date
October 31, 2010
Pyridostigmine
Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
Placebo
If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
Mayo Clinic, Rochester
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
National Center for Research Resources (NCRR)
NIH
Mayo Clinic
OTHER